- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00626483
Basiliximab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia (REGULATe)
REGULATory T-Cell Inhibition With Basiliximab (Simulect®) During Recovery From Therapeutic Temozolomide-induced Lymphopenia During Antitumor Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed Glioblastoma Multiforme
RATIONALE: Monoclonal antibodies, such as basiliximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Vaccines may help the body build an effective immune response to kill tumor cells. Giving these treatments together may kill more tumor cells. Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) is a powerful adjuvant capable of stimulating macrophage function, inducing proliferation and maturation of DCs, and is able to enhance T-lymphocyte stimulatory function. Intradermal administration of GM-CSF enhances the immunization efficacy at the site of administration
PURPOSE: This clinical trial is studying how well basiliximab works in treating patients with newly diagnosed glioblastoma multiforme and temozolomide-caused lymphopenia who are undergoing targeted immunotherapy.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES:
Primary
- To determine if basiliximab inhibits the functional and numeric recovery of T-regulatory cells after therapeutic temozolomide (TMZ)-induced lymphopenia in the context of vaccinating adult patients with newly diagnosed glioblastoma multiforme (GBM) using cytomegalovirus (CMV) pp65-lysosomal-associated membrane protein (LAMP) mRNA-loaded dendritic cells (DCs) with GM-CSF in patients who are seropositive and seronegative for CMV.
Secondary
- To evaluate the safety of basiliximab in these patients.
- To determine if basiliximab enhances the magnitude or character of pp65-specific vaccine-induced cellular or humoral immune responses, inhibits or enhances activation-induced cell death, or induces immunologic or clinical evidence of autoimmunity.
- To determine if basiliximab alters the phenotype (CD56 expression), cytokine secretion profile, or cytotoxicity of CD3-CD56+ natural killer cells.
- To determine if basiliximab in addition to vaccination extends progression-free survival compared to historical cohorts.
- To characterize immunologic cell infiltrate in recurrent tumors and seek evidence of antigen-escape outgrowth.
OUTLINE: Patients undergo leukapheresis for generation of dendritic cells (DCs) after resection. After initial leukapheresis, all patients undergo stereotactic radiotherapy (RT) on days 1-5 and concurrent temozolomide (TMZ) IV on days 1-7 for 6.5 weeks in the absence of disease progression or unacceptable toxicity.
Beginning 3 weeks after completion of RT, patients receive TMZ IV on days 1-5. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity. On day 14 ± 2 days of this first cycle of TMZ, patients will receive basiliximab, which is 7 days (± 2 days) before DC vaccine #1 and 2 weeks later, a second dose of basiliximab will be given, which is also 7 days before vaccine # 2.
All patients will undergo leukapheresis again for DC generation and immunologic monitoring with specific assessment of baseline antigen-specific cellular and humoral immune responses 3 + 1 weeks after vaccine #3.
Patients will then be treated monthly with TMZ cycles for a total of 12 cycles . On day 21 ± 2 days of each TMZ cycle, patients will receive monthly vaccines for a total of 8 vaccines. Patients will have blood drawn for immunologic monitoring before basiliximab infusions and prior to vaccines 1, 2, 3, and prior to monthly vaccines and then bimonthly through TMZ cycles without receiving any other prescribed antitumor therapy until progression.
After completion of study treatment, patients are followed every 2 months.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Histopathologically confirmed glioblastoma multiforme
- WHO grade IV disease
- Must undergo leukapheresis ≤ 4 weeks after definitive resection
Residual radiographic contrast enhancement on post-resection CT scan or MRI must not exceed 1 cm in diameter in two perpendicular axial planes
- Patients with evidence of contrast enhancement exceeding 1 cm in diameter in two perpendicular axial planes after radiation will not be a candidate for the vaccine despite being previously enrolled and will be removed from the study and replaced
- No radiographic or cytologic evidence of leptomeningeal or multicentric disease
PATIENT CHARACTERISTICS:
- Karnofsky performance status 80-100%
- Curran Group status I-IV
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No active infection requiring treatment
- No unexplained febrile (>101.5°F) illness
- No known immunosuppressive disease or known HIV infection
- No unstable or severe intercurrent medical conditions such as severe heart or lung disease
No allergy to temozolomide (TMZ) or otherwise unable to tolerate TMZ for reasons other than lymphopenia
- Patients who are found after enrollment to be unable to tolerate TMZ will not be a candidate for the vaccine despite being previously enrolled and will be removed from the study and replaced
- No prior allergic reaction to daclizumab or one of its components
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- No prior daclizumab
- No other prior conventional therapeutic intervention except for steroids, radiation, or temozolomide
- No prior inguinal lymph node dissection, radiosurgery, brachytherapy, or radiolabeled monoclonal antibodies
No concurrent corticosteroids, with the exception of nasal or inhaled steroids, at a dose above physiologic levels
- Patients requiring an increase in corticosteroids, with the exception of nasal or inhaled steroids, such that at the time of first vaccination they require a dose above physiologic levels, will be removed from the study and replaced (physiologic dose will be defined as < 2 mg of dexamethasone/day)
- Once vaccinations have been initiated, if patients subsequently require increased steroids, they will still be permitted to remain on the study, but every effort will be made to minimize steroid requirements
- No prior allogeneic solid organ transplantation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CMV pp65-LAMP mRNA-loaded DC vaccination
Basiliximab will be safe in combination with CMV pp65-LAMP mRNA-loaded DC vaccination and GM-CSF
|
Only one dose of DCs (2 x 10^7) is being assessed.
Basiliximab 20 mg and 40 mg is being assessed depending on dose-cohort enrollment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Functional capacity of CD4+,CD25+, CD127- T-regulatory cells
Time Frame: Approximately 26 months at time of brain tumor progression
|
Functional and quantitative recovery of regulatory T cells is measured during and following study treatment and at the time of tumor progression, which is estimated to be about 26 months from time of diagnosis based on expected progression free survival rates with standard of care therapy.
|
Approximately 26 months at time of brain tumor progression
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of CMV pulsed pp65 DC vaccines
Time Frame: 2 months following last vaccine administration
|
Number of patients experiencing WHO Grade 3, 4, and 5 adverse events considered possibly, probably, or definitely related to study treatment
|
2 months following last vaccine administration
|
Effect of basilixiumab on pp65 vaccine
Time Frame: 1 year
|
Determine if basiliximab enhances the magnitude or character of pp65-specific vaccine-induced cellular or humoral immune responses, inhibits or enhances activation-induced cell death, or induces immunologic or clinical evidence of autoimmunity
|
1 year
|
Effect of basilixiumab on immune profiles
Time Frame: 1 year
|
Determine if basiliximab alters the phenotype (CD56-expression), cytokine secretion profile, or cytotoxicity of CD3-CD56+ NK cells
|
1 year
|
Progression-free survival (PFS)
Time Frame: 1 year
|
Time in months from the start of study treatment to the date of first progression according to RANO criteria, or to death due to any cause.
Patients alive who had not progressed as of the last follow-up had PFS censored at the last follow-up date.
Median PFS was estimated using a Kaplan-Meier curve.
|
1 year
|
Characterize immune cells in recurrent tumors
Time Frame: 1 year
|
Characterize immunologic cell infiltrate in recurrent tumors and seek evidence of antigen escape outgrowth
|
1 year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Mustafa Khasraw, MD, Duke University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms, Glandular and Epithelial
- Hematologic Diseases
- Astrocytoma
- Glioma
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Leukopenia
- Leukocyte Disorders
- Neoplasms
- Glioblastoma
- Lymphopenia
- Physiological Effects of Drugs
- Immunosuppressive Agents
- Immunologic Factors
- Basiliximab
Other Study ID Numbers
- Pro00000581
- P30CA014236 (U.S. NIH Grant/Contract)
- P50CA108786 (U.S. NIH Grant/Contract)
- SPORE Project 3
- CDR0000579683 (Other Identifier: National Cancer Institute)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Neoplasms Brain
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingMetastatic Malignant Neoplasm in the Brain | Malignant Brain Neoplasm | Recurrent Malignant Brain NeoplasmUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingMalignant Brain Neoplasm | Recurrent Malignant Brain Neoplasm | Refractory Malignant Brain NeoplasmUnited States
-
University of California, San FranciscoGilead SciencesSuspendedBrain Cancer | Malignant Brain Tumor | Brain Tumor Adult | Recurrent Brain Tumor | Progressive Malignant Brain Tumor | Brain Tumor, PediatricUnited States
-
ABM Therapeutics Shanghai Company LimitedRecruitingPrimary Malignant Brain TumorChina
-
Jonsson Comprehensive Cancer CenterWithdrawnBrain Tumor | Malignant Neoplasm, BrainUnited States
-
University Hospital, LilleMinistry of Health, FranceTerminatedMalignant Brain TumorFrance
-
Novelwise Pharmaceutical CorporationRecruitingMalignant Neoplasm | Malignant Neoplasm of BrainTaiwan
-
Darell D. Bigner, MD, PhDNational Institute of Neurological Disorders and Stroke (NINDS)Terminated
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingMalignant Neoplasm | Metastatic Malignant Neoplasm in the BrainUnited States
-
Assistance Publique - Hôpitaux de ParisGustave Roussy, Cancer Campus, Grand Paris; Institut Curie; CarTheraRecruitingMalignant Glioma | Embryonal Tumor | Malignant Brain TumorFrance
Clinical Trials on RNA-loaded dendritic cell vaccine
-
National Cancer Institute (NCI)TerminatedMelanoma | Breast Cancer | Pancreatic Cancer | Ovarian Cancer | Gastrointestinal CancerUnited States
-
Duke UniversityNational Cancer Institute (NCI)Completed
-
Radboud University Medical CenterCompletedColorectal Cancer | Liver MetastasesNetherlands
-
University Hospital ErlangenUniversity Hospital, Essen; University Hospital Tuebingen; Universitätsklinikum... and other collaboratorsActive, not recruiting
-
N.N. Petrov National Medical Research Center of...UnknownSarcoma | Neoplasms, Connective and Soft TissueRussian Federation
-
Hospital Clinic of BarcelonaCompleted
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)WithdrawnHematopoietic and Lymphoid System Neoplasm | Cytomegaloviral InfectionUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)TerminatedRecurrent Renal Cell Carcinoma | Stage I Renal Cell Cancer | Stage II Renal Cell CancerUnited States
-
Jan WalewskiCompletedLymphoma | Multiple Myeloma and Plasma Cell NeoplasmPoland
-
University of FloridaUniversity of California, San Francisco; Florida Department of Health; Pacific... and other collaboratorsRecruiting